EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Integrating innate and adaptive immunity in oncolytic virus therapy

Kristin DePeaux, Greg M Delgoffe

Trends in Cancer · 2024-02 · 10 (2) · 135-146

DOI: 10.1016/j.trecan.2023.09.012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2024-02. Verfasst von Kristin DePeaux und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center…. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Oncolytic Viruses, Neoplasms. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncolytic viruses (OVs), viruses engineered to lyse tumor cells, work hand in hand with the immune response. While for decades the field isolated lytic capability and viral spread to increase response to virotherapy, there is now a wealth of research that demonstrates the importance of immunity in the OV mechanism of action. In this review, we will cover how OVs interact with the innate immune system to fully activate the adaptive immune system and yield exceptional tumor clearances as well as look forward at combination therapies which can improve clinical responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirotherapyOncolytic VirusesNeoplasmsHumansAdaptive ImmunityCombined Modality Therapy

Stichwörter der Autor:innen

adjuvant therapybioengineeringimmunosuppressionimmunotherapyoncolytic virussynthetic biology

Autor:innen und Institutionen

  • Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. Electronic address: gdelgoffe@pitt.edu.

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • National Cancer Institute
  • The Mark Foundation for Cancer Research
  • Medical Center, University of Pittsburgh
  • Stand up to Cancer
  • National Institute of Allergy and Infectious Diseases
  • Cancer Research Institute

Zitieren

APA

DePeaux, K., & Delgoffe, G. M. (2024). Integrating innate and adaptive immunity in oncolytic virus therapy. Trends in Cancer, 10(2), 135-146. https://doi.org/10.1016/j.trecan.2023.09.012

Vancouver

DePeaux K, Delgoffe GM. Integrating innate and adaptive immunity in oncolytic virus therapy. Trends in Cancer. 2024;10(2):135-146. doi:10.1016/j.trecan.2023.09.012

BibTeX
@article{DePeaux2024,
  author = {DePeaux, Kristin and Delgoffe, Greg M},
  title = {Integrating innate and adaptive immunity in oncolytic virus therapy},
  journal = {Trends in Cancer},
  year = {2024},
  volume = {10},
  number = {2},
  pages = {135--146},
  doi = {10.1016/j.trecan.2023.09.012}
}
Kostenlos starten →